COVID-19 Severity Test Reads Immune System in Real Time Using Machine Learning for Predicting Severe Outcomes

A new COVID-19 test reads the immune-system in real time to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome.

MeMed (Haifa, Israel) has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity - a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes. The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.

MeMed COVID-19 Severity is a predictive and actionable patient management tool. The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management. MeMed has recently published the results from a multinational derivation study, demonstrating the signature’s ability to accurately predict severe COVID-19 respiratory failure. The company has completed an additional independent multinational validation study; the results will be revealed in coming months.

“I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation,” said Eran Eden, MeMed’s co-founder and CEO. “MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics. It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians,” said Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center. “As an ER doctor myself, I am fascinated by the potential for host immune response technologies to help predict patient outcomes. Tools like MeMed COVID-19 Severity are a win-win solution: doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low.”

Related Links:
MeMed